Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR17031 vs insulin glargine in type 2 diabetes
NCT06871761Phase 3Completed
- Sponsor
- Hengrui
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui. Primary endpoint: Changes in HbA1c from baseline to week 26. Started May 2024; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06871761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871761.